Talaris Therapeutics, Inc. (TALS) News

Talaris Therapeutics, Inc. (TALS): $2.82

-0.08 (-2.76%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add TALS to Watchlist
Sign Up

Industry: Biotech


Ranked

of 400

in industry

Filter TALS News Items

TALS News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest TALS News From Around the Web

Below are the latest news stories about Talaris Therapeutics Inc that investors may wish to consider to help them evaluate TALS as an investment opportunity.

Talaris Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

BOSTON and LOUISVILLE, Ky., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced that Scott Requadt, Chief Executive Officer of Talaris, will present in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on Friday, February 18, 2022 at 8:40 AM ET.

GlobeNewswire | February 11, 2022

We're Hopeful That Talaris Therapeutics (NASDAQ:TALS) Will Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Yahoo | February 8, 2022

Altium Wealth Management LLC Buys Vanguard FTSE Emerging Markets ETF, Invesco Variable Rate ...

Investment company Altium Wealth Management LLC (Current Portfolio) buys Vanguard FTSE Emerging Markets ETF, Invesco Variable Rate Preferred ETF, Charles Schwab Corp, Hartford Municipal Opportunities ETF, Talaris Therapeutics Inc, sells Banco Santander SA, Federal Realty Investment Trust, Sysco Corp, Rockwell Automation Inc, iShares MSCI EAFE Small-Cap ETF during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Altium Wealth Management LLC.

Yahoo | January 31, 2022

Talaris Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

BOSTON and LOUISVILLE, Ky., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced that Scott Requadt, Chief Executive Officer of Talaris, will present at the virtual 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 2:15 PM ET. A live webcast o

Yahoo | January 6, 2022

Talaris Therapeutics to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference

BOSTON and LOUISVILLE, Ky., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced that Scott Requadt, Chief Executive Officer of Talaris, will present at the H.C. Wainwright BioConnect 2022 Virtual Conference being held January 10-13, 2022. A webcast of the pre-recorded pre

Yahoo | January 4, 2022

Talaris Therapeutics Announces Addition to the Nasdaq Biotechnology Index

BOSTON and LOUISVILLE, Ky., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc., (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe non-malignant blood, immune and metabolic disorders, today announced that the company has been added to the NASDAQ Biotechnology Index (NASDAQ: NBI), active prior to market open today. The N

Yahoo | December 20, 2021

Talaris Therapeutics (NASDAQ:TALS) Shares Gap Down to $12.92

Shares of Talaris Therapeutics, Inc. (NASDAQ:TALS) gapped down prior to trading on Friday . The stock had previously closed at $12.92, but opened at $12.20. Talaris Therapeutics shares last traded at $12.46, with a volume of 1,005 shares traded. Several analysts have commented on TALS shares. Zacks Investment Research cut shares of Talaris Therapeutics from []

Transcript Daily | December 17, 2021

Talaris Therapeutics Presents High-Resolution Analysis of HLA Mismatching in Phase 2 Trial in Living Donor Kidney Transplant

Analysis confirms FCR001 induced durable tolerance in highly mismatched related and unrelated recipients Analysis confirms FCR001 induced durable tolerance in highly mismatched related and unrelated recipients

Intrado Digital Media | December 14, 2021

Charles Schwab Investment Management Inc. Invests $330,000 in Talaris Therapeutics, Inc. (NASDAQ:TALS)

Charles Schwab Investment Management Inc. acquired a new position in shares of Talaris Therapeutics, Inc. (NASDAQ:TALS) in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 22,410 shares of the companys stock, valued at approximately $330,000. Several other hedge funds have also recently added to or reduced []

Dakota Financial News | December 2, 2021

Talaris Therapeutics (NASDAQ:TALS) Shares Gap Down to $13.62

Talaris Therapeutics, Inc. (NASDAQ:TALS)s stock price gapped down prior to trading on Tuesday . The stock had previously closed at $13.62, but opened at $13.14. Talaris Therapeutics shares last traded at $13.44, with a volume of 36 shares trading hands. Several equities research analysts have recently issued reports on the company. Evercore ISI reaffirmed a []

Transcript Daily | November 30, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 1.2357 seconds.